• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Redeye: AVTECH (Q3 Review) - Medium-term upside recognised

AVTECH Sweden

AVTECH’s sales grew 43% y/y, driven by new agreements, while USD/SEK was a small headwind. However, net sales and EBITDA were 11% and 9% below Redeye’s forecast, respectively (in line with the pre-announcement). Redeye revises its net sales estimate by 5% for 2025-2028, resulting in an 8-10% EBIT revision for the same period. Redeye reduces its Base Case by 8%. On Redeye’s updated EBIT estimates, AVTECH’s EV/EBIT NTM aligns with its 3-year average. Redeye views new agreements as the primary driver for the share, while the main risk consists of upcoming contract renewals in 2026.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


AVTECH (Q3 Review) - Medium-term upside recognised